Xalkori and Sepsis - a phase IV clinical study of FDA data

Summary:

Sepsis is reported as a side effect among people who take Xalkori (crizotinib), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Synthroid, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Sepsis when taking Xalkori. It is created by eHealthMe based on reports of 9,640 people who have side effects when taking Xalkori from the FDA, and is updated regularly.

What is Xalkori?

Xalkori has active ingredients of crizotinib. eHealthMe is studying from 9,659 Xalkori users. Check the latest studies of Xalkori.

What is Sepsis?

Sepsis (a severe blood infection that can lead to organ failure and death) is found to be associated with 2,525 drugs and 3,260 conditions by eHealthMe. Check the latest studies of Sepsis.

On Aug, 05, 2026

9,640 people reported to have side effects when taking Xalkori.
Among them, 42 people (0.44%) have Sepsis.

Among these 42 people:

How long have people been on Xalkori when they have Sepsis? *

What is the gender of people who have Sepsis when taking Xalkori? *

female: 50 %
male: 50 %

What is the age of people who have Sepsis when taking Xalkori? *

What are other drugs people take besides Xalkori? *

What are other side effects people have besides Sepsis? *

Pneumonia: 7 people, 16.67%
Neoplasm Progression (growth of tumour): 6 people, 14.29%
Acidosis (build-up of carbon dioxide in the blood): 6 people, 14.29%
Systemic Candida (whole body fungal infection): 6 people, 14.29%
Diarrhea: 5 people, 11.90%
Pleural Effusion (water on the lungs): 5 people, 11.90%
Ascites (accumulation of fluid in the abdominal cavity): 4 people, 9.52%
Death: 3 people, 7.14%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 7.14%
Gastrointestinal Perforation (hole in the digestive tract): 3 people, 7.14%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 12 people, 28.57%
Lung Cancer - Non-Small Cell (lung cancer): 10 people, 23.81%
Epithelioid Sarcoma Metastatic (cancer of fingers, hands, and forearms-metastatic): 6 people, 14.29%
Epithelioid Sarcoma (cancer of fingers, hands, and forearms): 5 people, 11.90%
Sarcoma Metastatic (rare cancers that develop in the muscle, bone, nerves, cartilage, tendons, blood vessels and the fatty and fibrous tissues spreads to other parts): 2 people, 4.76%
Neoplasm Malignant (cancer tumour): 2 people, 4.76%
Wheezing (a high-pitched whistling sound made while you breath): 1 person, 2.38%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 2.38%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 2.38%
Blood Glucose Decreased: 1 person, 2.38%

* Approximation only. Some reports may have incomplete information.

Do you take Xalkori and have Sepsis?

- Check whether Sepsis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xalkori:

Xalkori (9,659 reports)

Sepsis treatments and more:

Sepsis (140,102 reports)

Browse all side effects of Xalkori:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Sepsis:

Sepsis (2,525 drugs)

Browse all the conditions that are associated with Sepsis:

Sepsis (3,260 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on crizotinib (the active ingredients of Xalkori) and Xalkori (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.